With the rise in resistance to antibiotics such as methicillin, there is a need for new drugs. We report here the discovery and X-ray crystallographic structures of 10 chemically diverse compounds (benzoic, diketo, and phosphonic acids, as well as a bisamidine and a bisamine) that inhibit bacterial undecaprenyl diphosphate synthase, an essential enzyme involved in cell wall biosynthesis. The inhibitors bind to one or more of the four undecaprenyl diphosphate synthase inhibitor binding sites identified previously, with the most active leads binding to site 4, outside the catalytic center. The most potent leads are active against Staphylococcus aureus [minimal inhibitory concentration (MIC) 90 ∼0.25 μg/mL], and one potently synergizes with methicillin (fractional inhibitory concentration index = 0.25) and is protective in a mouse infection model. These results provide numerous leads for antibacterial development and open up the possibility of restoring sensitivity to drugs such as methicillin, using combination therapies. drug discovery | in silico high-throughput screening | peptidoglycan | protein structure
With the rise in resistance to antibiotics such as methicillin, there is a need for new drugs. We report here the discovery and X-ray crystallographic structures of 10 chemically diverse compounds (benzoic, diketo, and phosphonic acids, as well as a bisamidine and a bisamine) that inhibit bacterial undecaprenyl diphosphate synthase, an essential enzyme involved in cell wall biosynthesis. The inhibitors bind to one or more of the four undecaprenyl diphosphate synthase inhibitor binding sites identified previously, with the most active leads binding to site 4, outside the catalytic center. The most potent leads are active against Staphylococcus aureus [minimal inhibitory concentration (MIC) 90 ∼0.25 μg/mL], and one potently synergizes with methicillin (fractional inhibitory concentration index = 0.25) and is protective in a mouse infection model. These results provide numerous leads for antibacterial development and open up the possibility of restoring sensitivity to drugs such as methicillin, using combination therapies. drug discovery | in silico high-throughput screening | peptidoglycan | protein structure T argeting isoprenoid biosynthesis is a potentially important route for antibiotic discovery because isoprenoids are involved in the very early steps of bacterial cell-wall biosynthesisthe condensation of dimethylallyl diphosphate (DMAPP, 1) with two molecules of isopentenyl diphosphate (IPP, 2) to form farnesyl diphosphate (FPP, 3), catalyzed by the enzyme farnesyl diphosphate synthase (FPPS), followed by the addition of eight more IPP molecules to form undecaprenyl diphosphate (UPP, 4) (1, 2) ( Fig. 1 ). Formation of 4 is catalyzed by the enzyme undecaprenyl diphosphate synthase (UPPS), and several UPPS inhibitors have been reported (3) (4) (5) (6) (7) (8) (9) (10) . UPP is then hydrolyzed to the monophosphate, which is next converted to lipid I and lipid II, leading to formation of cell wall peptidoglycan ( Fig. 1) (11, 12) . Antibiotics such as methicillin and vancomycin act in the latter stages of peptidoglycan formation, again as shown in Fig. 1 . Here, we focus on the development of UPPS inhibitors because UPPS is an essential protein not produced by humans (13) . UPPS inhibitors are predicted to synergize with the more-conventional cell-wall biosynthesis inhibitors, potentially reducing the toxicity of drugs such as vancomycin (by decreasing dosage), or restoring drug sensitivity [e.g., with methicillin-resistant Staphylococcus aureus (MRSA)]. The UPPS structure is unusual in that there are four known ligand binding sites (5) , opening up the possibility of designing a diverse range of inhibitors.
Results and Discussion UPPS Inhibitors. In previous work, we and others reported the discovery of several UPPS inhibitors, including bisphosphonates such as BPH-629 (5) (5) , tetramic acids such as 6 (6), as well as diketoacids such as 7 (10) and benzoic acids such as 8 (9) (Fig. 2 ). Based on in silico high-throughput screening (9) and hit development ( Fig. S1 ), we produced a small series of benzoic (9) (10) (11) (12) , phosphonic (13) , and diketoacids (14, 15 ) that had activity against UPPS (Fig. 2 ). In addition to these anionic species, we discovered several potent cationic inhibitors (16) (17) (18) ; this was unexpected from both a computational and experimental standpoint because these compounds do not mimic the (anionic) FPP substrate, and the UPPS mechanism is not thought to involve carbocation intermediates (14) . We thus sought to determine how these inhibitors bind to their UPPS target, by obtaining crystal structures of 8-16 and 18 bound to Escherichia coli UPPS.
Four Inhibitor Binding Sites in UPPS. UPPS functions by sequentially adding IPP to an allylic substrate, initially FPP (15) . It might reasonably be expected, then, that anionic inhibitors with lipophilic side-chains would bind to the FPP substrate site, as shown in Fig. 3A , yellow (PDB ID code 1X06). However, in a second structure (PDB ID code 1V7U), two FPP molecules bind, one in the substrate site and the other in a second site at the "bottom" of the protein (Fig. 3A, green) . Moreover, with the bisphosphonate inhibitor 5, there are actually four binding sites (sites 1-4) (5) that can be occupied ( Fig. 3B , cyan; PDB ID code 2E98) in which the side chains in each of the four inhibitor molecules occupy the large hydrophobic center of the protein that normally accommodates the C 55 side chain in the UPP product. With the two less-active benzoic acid inhibitors, 8 and 9, we find that only site 3 ( Fig. 3C ; PDB ID code 3SGT) or sites 1, 2, and 3 are occupied ( Fig. 3D ; PDB ID code 3SGV), but the activity of both of these inhibitors is weak (8, E. coli UPPS, IC 50 = 150 μM; S. aureus UPPS, 170 μM; 9, E. coli UPPS, IC 50 = 35 μM, S. aureus UPPS, 72 μM; Table S1 ). Full data acquisition and structure refinement details are in Table S2 , and electron densities (2Fo-Fc and simulated-annealing Fo-Fc omit maps) are in Fig. S2 A and B. So, with these two benzoic acid inhibitors, binding to sites 1, 2, or 3 correlates only to weak UPPS inhibition.
Potent Benzoic Acid Inhibitors Bind to Site 4. We next determined the structures of the three potent benzoic acid inhibitors (10-12) ( Fig. 2 ) bound to UPPS ( Fig. 4 A-C). Each of these molecules contains a long hydrophobic side-chain and, on average, the IC 50 values against both E. coli and S. aureus UPPS are ∼3 μM (Table S1) . What is notable about these X-ray structures is that in each case, site 4 is occupied, together with either sites 1, 2, or 3. Full data acquisition and structure refinement details are in Table S2 , and electron densities are in Fig. S2 A and B. In addition, we found that the aryl phosphonate inhibitor 13 also occupied two sites ( Fig. 4D ). However, there are two chains in one asymmetric unit, and site occupancies in the two chains are variable: the lower site-occupancy chains are shown in Fig. S2C . These four structures suggest that good UPPS inhibition correlates with occupancy of site 4.
Diketoacids, a Bisamidine and a Bisamine also Target Site 4. In previous work (10), we found that the diketoacid 15 had potent cell-growth inhibition activity with the following minimal inhibitory concentration (MIC) 90 values: 0.25-0.5 μg/mL against S. aureus; 0.5 μg/mL against Bacillus anthracis; 4 μg/mL against Listeria monocytogenes and Enterococcus faecium; and 1 μg/mL against Streptococcus pyogenes, but little toxicity toward human cell lines (>20 μM). We therefore determined the structure of 15 and a second diketoacid (14) , bound to UPPS. As seen in Fig. 5 A and B, both diketoacids bind to site 4, with 14 also binding to site 3. The observation that 15 binds only to site 4 is of interest because this inhibitor has very good antibiotic activity (10) . Plus, the occupation of site 4 in both structures is consistent with the results for the other potent anionic inhibitors ( Fig. 4) .
A surprising result from the in silico screening work ( Fig. S1 ) was that bisamidines such as 16 had modest activity against UPPS. Moreover, the biphenyl bisamidine 17 showed potent activity against UPPS (IC 50 = 0.1 μM) as well as a MIC 90 of 0.25 μg/mL against S. aureus (USA300, MRSA strain). We also found that another dicationic species 18 was a UPPS inhibitor active against S. aureus (Table S1 ). We were unable to obtain the structure of 17 bound to UPPS, but we did obtain structures of 16 and 18 bound to UPPS. With these two cationic inhibitors, rather than two individual molecules binding, we observe that a single molecule binds, with its polar, cationic groups located at or near the protein's surface, whereas the hydrophobic "spacer" is buried inside the protein's hydrophobic interior, ( Fig. 5 C and D; PDB ID codes 4H2J and 4H2M). Though we did not succeed in crystallizing the most potent lead 17, a similar "polar-hydrophobic-polar" binding arrangement in which the biphenyl group is buried seems very likely for this species also, and is supported by the results of computational docking, as shown in Fig. S2D .
Comparison of E. coli and S. aureus UPPS Structures and Their
Inhibition. In this work, we determined the activity of each inhibitor against both E. coli UPPS and S. aureus UPPS, finding that there is a very good correlation (R 2 = 0.8) between the 14 sets of pIC 50 (= −log 10 IC 50 ) values (Table S1; Fig. S3A ); this is not unexpected because 18 of the top 20 residues in a SCORE-CONS (16) analysis of E. coli UPPS are present in S. aureus UPPS and most other bacterial UPPSs (Table S3 ). We were not able to determine the X-ray structures of any inhibitor bound to S. aureus UPPS, but we did determine the structure of the protein with a bound FPP (PDB ID code 4H8E; full data acquisition and structure refinement details are in Table S4 ). S. aureus UPPS cocrystallized with FPP in site 1, together with a SO 4 2− in the IPP binding site, as reported in a patent application (17) . A superposition of the S. aureus and E. coli proteins is shown in Fig. S3B , where we find a Cα rmsd of 0.91 Å over 202 residues, indicating that both structures are very similar [in the presence of FPP/FSPP (S-thiolo-FPP) and either IPP or SO 4 2− ], consistent with the pIC 50 correlation.
Relationship to Other Inhibitors: Is UPPS a Missing Link? The structures of several of the UPPS inhibitors described here are similar to (and with 18, the same as) those being developed as antiinfective drug leads but whose mechanisms of action are not clear. For example, the chemical structures of the benzoic acid inhibitors are similar to those of anthranilic (ortho-aminobenzoic) acids reported by Larsen et al. (18) and Mott et al. (19) having activity against S. aureus. The molecular mechanism of action of these inhibitors was initially thought to involve inhibition of translation/termination, but in later work this inhibition was not found to correlate with cell growth inhibition, and a new target (SA1575, of unknown function), as well as inhibition of cell wall biosynthesis, was reported. We find that a pharmacophore model ( Fig. 6A ) of seven potent benzoic acid UPPS inhibitors we synthesized ( Fig. S4A ) is very similar to that obtained for S. aureus cell growth inhibition ( Fig. 6B ) using five structures reported by Larsen et al. (Fig. S4B ), making UPPS inhibition one likely mechanism for these inhibitors-in particular because they are already known to inhibit cell wall biosynthesis. In addition, we found that the lead 19 reported by Larsen et al. (18) is a ∼1 to 2 μM UPPS inhibitor (Table S1) , consistent with a role in S. aureus growth inhibition.
In addition to the benzoic/anthranilic acids, there is also interest in the mechanisms of action of bisamidines, such as 20 (20, 21) , as well as of other cationic species, such as 21 (22) , and it has been proposed that these and related compounds could bind to the minor groove of DNA (20) , or that they could alter lipid bilayer structure (23) (24) (25) , as illustrated schematically in Fig. 6 C and D. Based on our crystallographic ( Fig. 5 C and D) as well as enzyme inhibition results, it is clear, however, that in addition to these binding modes, polar-hydrophobic-polar inhibitors (such as 17 or 18) can also bind to proteins, as shown in the cartoon in Fig. 6E , with their polar headgroups located near polar protein residues (or at the protein/water interface), whereas their hydrophobic centers are buried inside the protein target ( Fig. 5 C and D) .
Notably, as with the benzoic acids, bisamidines such as 20 can inhibit cell wall biosynthesis, and with 20 we find quite potent (470 nM) UPPS inhibition.* The ability to inhibit UPPS in addition to, e.g., DNA and lipid membrane targeting likely contribute to the potent activity of these compounds and, in some cases, the lack of resistance observed experimentally. In addition, it is also possible that other prenyltransferases, such as FPPS, may in some cases be targeted.
Synergy and in Vivo Results. The UPPS inhibition results suggested to us the possibility of synergistic activity with downstream cellwall biosynthesis inhibitors, such as methicillin ( Fig. 1) ; this is indeed the case, as shown in Fig. 7A in which we present the isobologram (26) for 17 + methicillin against a USA300 strain of MRSA. We observe a potent synergistic interaction with a fractional inhibitory concentration index (FICI), defined as (27, 28) . Using this method, FICI values <0.5 represent synergism; >0.5 and <1.0 represent additivity; >1 and <2 represent an indifferent effect; and ≥2 represents drug antagonism (29) . An FICI = 0.25 thus represents strong synergism, opening up the probability of restoring drug sensitivity in drug-resistant strains. However, are such compounds active in in vivo models of infection?
In previous work, it has been found that, e.g., benzoic acids (such as 19) as well as tetramic acids (such as 6) have potent activity against bacteria; however, there have been no previous reports of in vivo activity, due perhaps to strong binding to plasma proteins. Because 17 had potent activity against UPPS (110 nM), we tested it in a mouse model of infection using the USA200 Sanger 252 (MRSA) strain of S. aureus. As can be seen in Fig. 7B , mice treated postinfection only with vehicle control all died, whereas mice treated with 17 (20/20 total, pooled results of two experiments) survived with no apparent adverse reactions.
Computational Results: FTMap, Principal Component, and Receiver
Operating Characteristic/Area Under the Curve Analyses. The results described above represent the discovery of a series of UPPS inhibitors-drug leads-some of which have potent activity in cells and a mouse infection model. From a structural perspective, the most surprising result was that the most potent inhibitors all bound to site 4, not the substrate site, site 1. In previous work on bisphosphonate UPPS inhibitors (5) we found that a wide range of bisphosphonates bound to site 1, and that enzyme inhibition and site 1 docking scores were highly correlated (5) . However, with all of the nonbisphosphonate inhibitors described here, we find that binding to site 4 is the common structural denominator for ligands with high affinity. Other sites are also often occupied, with either two molecules binding, or one inhibitor spanning two sites (sites 4 and 2, with the dicationic species).
Site 4 is quite removed from the most-flexible loop region (residues 72-82) of the active site, suggesting that there may be fewer entropic costs due to constraining this loop, associated with inhibitor binding to site 4, rather than to sites 1-3, where the ligand directly contacts and restrains the loop. Site 4 is also predicted to be druggable when using the solvent-mapping program FTMap (30) , as shown in Fig. 8A , again supporting the idea that inhibitors that bind to site 4 will be good drug leads. With the nonbisphosphonate inhibitors, we also see that the global structures are quite similar to apo UPPS (Fig. 8B, red) , using principal component analysis (31) . The bisphosphonate inhibitors (blue) and substrate (yellow)-bound structures are altered to a greater extent from the apo form than are the nonbisphosphonate structures (red), which suggests less induced-fit occurs on binding, which again will reduce any energetic costs associated with protein conformational changes upon binding.
Finally, because many of these inhibitors were the result of virtual screening, we assessed the predictive nature of each structure using a receiver operating characteristic/area under the curve (ROC/ AUC) approach (32) with a 112-compound screening dataset ( , where AUC = 0.802. Taken together, these results strongly support the importance of developing compounds that bind to site 4 as UPPS inhibitor drug leads, and that computational models based on these structures can significantly enrich the hit rate.
Conclusions
The results we have described herein are of interest for several reasons. First, we obtained the X-ray structures of 10 UPPS inhibitors covering a diverse range of structures: benzoic acids, diketoacids, an aryl phosphonate, a bisamidine, and a bisamine. The surprising result was that both cationic as well as anionic compounds were inhibitors, the cationic species having an unusual polar-hydrophobic-polar structural motif. Second, we find evidence that occupancy of site 4 (not the FPP substrate site, site 1) correlates with the potent activity of these inhibitors, and that site 4 is predicted to be druggable. Third, we find that the cationic (bisamidine and a bisamine) inhibitors span both sites 2 and 4, with their polar groups at or near the protein/water interface, whereas their hydrophobic domains are buried. This result is of particular importance because this motif is very similar to that proposed to be important for DNA and lipid membrane binding with structurally related inhibitors, leading to the idea that such compounds may have multiple targets (including UPPS), thereby increasing potency. We also find that a closely related biphenyl analog (17) inhibits UPPS at ∼100 nM levels, has a MIC 90 of 0.25 μg/mL, and strongly synergistic activity (FICI = 0.25) with methicillin in an MRSA strain otherwise resistant to the antibiotic. In addition, this compound shows clear therapeutic activity in a mouse model of infection. Finally, we propose that anthranilic acids, known to be potent inhibitors of S. aureus growth that target cell-wall biosynthesis, also target bacterial UPPS. Taken together, these results open up additional routes to anti-infective therapies targeting bacterial isoprenoid biosynthesis, and suggest that in some cases drug leads that have been proposed to target DNA and lipid membrane structure may also target bacterial cellwall biosynthesis via UPPS inhibition.
Methods E. coli UPPS and S. aureus UPPS were expressed and purified as described previously (9) . UPPS inhibition assays were carried out as described pre-viously (5) . UPPS/inhibitor crystals were obtained via soaking as described previously (5) . Structure determinations and refinements were carried out basically as described previously (5), with full details given in SI Methods. For the 11 structures reported, the resolution was on average 1.88 Å (±0.29 Å), and R free was on average 24.6% (±3.9%). Full synthesis and characterization details for all compounds investigated crystallographically are provided in SI Methods. In vivo experiments used female BALB/c mice infected intraperitoneally with S. aureus (USA200), as described in detail in SI Methods. Bacterial cell-growth inhibition assays were carried out as described previously (10) . The care and experimental manipulation of our mice were reviewed and approved by the Institutional Animal Care and Use Committee at the University of California at San Diego.
Supporting Information
Zhu et al. 10 .1073/pnas.1219899110 SI Methods Synthetic Aspects. All reagents used were purchased from Aldrich or Alfa Aesar. NMR spectra were obtained on 400 MHz ( 1 H) or 500 MHz Varian Unity spectrometers. Chemical shifts are reported in parts per million (ppm) using tetramethylsilane as an external standard using the convention that high frequency, low field, paramagnetic or de-shielded values are positive. The structures 10, 14, and 15 were available from previous work (1, 2) . The syntheses of 11, 12, 13, 16, 17, and 18 are described below.
(Dodecyloxy)-6-Hydroxybenzoic Acid (11 in anhydrous THF (20 mL) was added Et 3 N (2.1 mL, 15 mmol) and the mixture was stirred at room temperature overnight. After filtration, the white solid was washed with water (20 mL) and ethyl acetate (10 mL) and then dried. Sodium hydrosulfide hydrate (100 mg), ethylenediamine (2 mL), and dimethylacetamide (10 mL) were then added and stirred overnight at 140°C. Upon removal of the solvent, the solid was washed thoroughly with water and then ethyl acetate (10 mL). To the suspension of the crude product in 10 mL of water were added two equivalents of methyl sulfonic acid. Removal of water afforded 17 as its methanesulfonic acid salt (1.44 g, 40%). 1 4 , and 25% PEG monomethyl ether 5,000) and then equilibrating with 400 μL mother liquor at room temperature. Bipyramidal crystals appeared overnight.
X-ray diffraction data for both E. coli UPPS and S. aureus UPPS were collected at the Life Science Collaborative Access Team 21-ID-D (F or G) at the Advanced Photon Source of Argonne National Laboratory. Diffraction data were processed and scaled using the program HKL3000 (HKL Research Inc.) (5) . The statistics for data collection are listed in Tables S2 and S4 .
The structures of the UPPS complexes were determined using a model prepared from the UPPS/BPH-629 complex structure (PDB ID code 2E98) with ligands and solvent removed. Structure refinements were carried out using Refmac (6, 7) , Phenix (8) , and COOT (9) . All structure figures were prepared with PyMOL (10). UPPS inhibition assays. E. coli UPPS and S. aureus UPPS inhibition assays were carried out as described previously (1) . Briefly, the condensation of FPP with isopentenyl diphosphate (IPP) catalyzed by UPPS was monitored by using a continuous spectrophotometric assay (11) in 96-well plates with 200-μL reaction mixtures containing 400 μM 7-methyl-6-thioguanosine (MESG), 350 μM IPP, 35 μM FPP, 25 mM Tris·HCl (pH 7.5), 0.01% Triton X-100, and 1 mM MgCl 2 . The IC 50 values were obtained by fitting the inhibition data to a standard rectangular hyperbolic dose-response function in GraphPad PRISM 4.0 software (GraphPad Software). The IC 50 values for the most active hits were verified by radiometric assay (12) with 2.5 μM FPP, 25 μM [ 3 H]IPP, and 0.01% Triton X-100.
Computational Aspects. Pharmacophore models were constructed in MOE (13) using the consensus pharmacophore module. The Glide (14-16) docking algorithm at the XP level (17) was used to perform all docking calculations with UPPS. X-ray structures were prepared with the protein preparation wizard (18) using standard parameters. Compounds were prepared with LigPrep (19) using standard parameters. For the calculation of the ROC/ AUC curves, 112 E. coli UPPS inhibitors with IC 50 < 100 μM were combined with the Schrödinger decoy library of 1,000 compounds (having an average molecular mass of 400 Da) (14, 16) . Compounds from this combined library were ranked by their Glide XP docking scores, and the AUC calculated.
Principal component analysis was performed using the monomer that had the most ligands present or, if not applicable, the most residues resolved. An invariant "core" of Cα atoms (20) was first determined, then structures were aligned with the core, and PCA analysis was performed using BIO3D (21) . The principal components plotted in Fig. 8B describe orthogonal eigenvectors with maximal variance. Hierarchical clustering was performed based on the Euclidian distance matrix of the first two principal components, then reduced to three groups of related "clusters" (22) . Cell growth inhibition. The growth of S. aureus (USA300 strain) and determination of minimal inhibitory concentration (MIC) values were as described previously (23) . E. coli growth and construction of isobolograms were also carried out basically as described previously (24) . In vivo experiments. Mice were infected i.p. with 10 9 cfu methicillinresistant Staphylococcus aureus (strain Sanger 252) suspended in 4% hog gastric mucin. At 1 h after infection, the mice were divided into two groups (n = 10 per group) and treated i.p. with either 17 (10 mg/kg) suspended in water or water alone (vehicle control). Treatment was continued once daily for two more days. Mortality was monitored twice daily. Fig. S1 . Schematic illustration of hit-to-lead development. FPPS inhibitors obtained by in silico screening of the National Cancer Institute Diversity Set II were screened against E. coli UPPS basically as described previously (1): the most potent hit (∼5 μM) was then used as a reference for a similarity search using SciFinder. A total of 22 compounds suggested were obtained from the National Institutes for Health Developmental Therapeutics Program. The most active lead was found to have ∼110 nM IC 50 values against both E. coli UPPS and S. aureus UPPS. 
